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A key part of the optimization of small molecules in
pharmaceutical inhibitor development is to vary the molecular
design to enhance complementarity of chemical features of the
compound with the positioning of amino acids in the active site
of a target enzyme. Typically this involves iterations of syn-
thesis, to modify the compound, and biophysical assay, to
assess the outcomes. Selective targeting of the anti-cancer
carbonic anhydrase isoform XII (CA XII), this process is
challenging because the overall fold is very similar across the
twelve CA isoforms. To enhance drug development for CA XII
we used a reverse engineering approach where mutation of the
key six amino acids in the active site of human CA XII into the
CA II isoform was performed to provide a protein chimera
(chCA XII) which is amenable to structure-based compound
optimization. Through determination of structural detail and
affinity measurement of the interaction with over 60 com-
pounds we observed that the compounds that bound CA XII
more strongly than CA II, switched their preference and bound
more strongly to the engineered chimera, chCA XII, based on
CA II, but containing the 6 key amino acids from CA XII,
behaved as CA XII in its compound recognition profile. The
structures of the compounds in the chimeric active site also
resembled those determined for complexes with CA XII, hence
validating this protein engineering approach in the develop-
ment of new inhibitors.
1. Introduction
The development of selective inhibitors targeted at structurally
highly similar enzyme isoforms is a challenging task in drug
discovery. Enzyme-inhibitor binding interactions occur via key
amino acids at defined positions, usually in the active site of the
enzyme. Identifying the bonding patterns of the residues
participating in the intermolecular interactions provides insight
into the catalytic mechanism and the opportunity for inhibitor
recognition.[1] In the case of inhibition of protein isoforms,
detecting the distinguishing amino acid interactions is crucial
for the design of isoform-selective inhibitors.
Carbonic anhydrases (CAs, EC 4.2.1.1) catalyze reversible
hydration of carbon dioxide to bicarbonate and protons. Their
isoforms play roles in numerous physiological and pathological
processes by regulating the pH and bicarbonate balance.[2–5] CA
inhibitors have been used as therapeutic options in a number
of disease areas including anti-glaucoma agents,[6,7] diuretics[8]
and antiepileptics.[9–12] However, most of the clinically used
inhibitors lack selectivity towards targeted CA isoforms and
exhibit various side effects. There is thus, a demand for selective
inhibitors that target only the disease-associated CA isoform, for
instance, isoforms IX or XII, which regulate the pH of a tumor
microenvironment.[13]
Design and development of CA isoform-selective inhibitors
is challenging due to the high amino acid sequence homology
between isoforms. Humans have twelve catalytically active CA
isoforms: CA I, CA II, CA III, CA VII, CA XIII (cytosolic), CA VA and
CA VB (mitochondrial), CA VI (secreted), CA IV, CA IX, CA XII, CA
XIV (membrane-bound). Active sites of CA isoforms are cone-
shaped and differ from each other by several residues.
CA XII is an important isoform since it controls the
extracellular pH of cancer cells under physiological conditions
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and acts as a hypoxia-induced tumor marker. CA XII is regulated
by estrogen receptor in breast cancer.[14] High expression of CA
XII correlates with favorable survival of patients having invasive
breast[15] or resectable non-small cell lung cancers.[16] However,
it is associated with poor prognosis in patients with
colorectal,[17] hepatocellular[18] carcinomas, and diffuse
astrocytomas.[19] Furthermore, CA XII is considered as a
pharmacological target to overcome chemoresistance in cancer
cells.[20] The lower wide-spread expression of CA XII has also
been detected in human eye,[21] gut,[22] kidney,[23] pancreas,[24]
gastric mucosa,[25] epithelial components of skin,[26] endometrial
epithelium[27] and male excurrent ducts.[28] Additional roles of
CA XII in the human body include glaucoma progression,[21] salt
uptake in sweat glands,[29] and pH regulation of nucleus
pulposus cells.[30] CA XII function in disease is reviewed in detail
by Waheed and Sly.[31]
CA XII is an important but highly challenging drug target.
Traditional screening and drug design protocols are limited
because it is a membrane-associated dimeric enzyme contain-
ing N-terminal extracellular catalytic domain, a membrane-
spanning α-helix, and a 30-residue small intracellular C-terminal
region. CA XII has been the focus of numerous studies to
determine its structure and function down to the atomic level.
The first crystallographic structure of CA XII at 1.55 Å resolution
was solved in 2001.[32] The protein has GXXXG and GXXXS
dimerization motifs in the transmembrane segment, two
glycosylation sites, Asn52 and Asn136, exposed on the surface
and a single disulfide linkage between Cys23 and Cys203. The
active site composition is analogous to the most studied CA II:
the zinc ion is coordinated by His94, His96, His119 and a water
molecule. The pKa of the zinc-bound water molecule at 25 °C is
7.0–7.1.[33,34] A large body of work has resulted in the deposition
of structural data for 24 crystal structures of chlorinated/
fluorinated mono-/di-substituted benzenesulfonamides bound
to CA XII complexes[35–42] to the PDB. This forms a valuable
resource for CA XII inhibitor design.
The high-resolution structural data is complemented by a
wealth of thermodynamic, kinetic and structural analysis of
interactions between more than 400 inhibitors and 12 CA
isoforms. These reveal that minor structural differences between
CA isoforms can cause unpredictable effects to the changes of
selective recognition between a ligand and target isoform.[43]
Most conserved residues are found deep within the active site
(close to the zinc ion),[44] whilst the top of the binding site is
more variable.
Here we use a protein engineering approach to produce a
chimeric version based on the CA II isoform which is soluble
and highly amenable to drug development strategies. In an
earlier study we showed that CA II-based mutant with six CA
XII-specific residues (A65S, N67K, I91T, F130A, V134S, and
L203N), resembled the active site of CA XII.[39] We, therefore,
produced a chimeric CA XII protein (chCA XII) which recapit-
ulates the CA XII enzyme activity and function. We have
characterized the catalytic activity and thermal stability of chCA
XII, as well as conducted ligand binding and inhibition studies
with 63 small molecule compounds by enzymatic and biophys-
ical assays. For the design of novel and selective anticancer
drug candidates we have analyzed the structural differences
between the targeted CA XII and off-target, ubiquitously
expressed, CA II, which share 34% sequence identity.[45] We
have obtained nine crystal structures of inhibitors bound to
chCA XII and compared the binding modes together with
binding affinities of inhibitors to CA II and CA XII. The detailed
analysis validates the protein engineering a route to selective
inhibitors of the CA XII isoform.
2. Results
The principal hypothesis and approach in constructing chCA XII
is shown in Figure 1. The chimeric protein produced is
essentially the same CA II, except that it would recognize
inhibitors that would be normally recognized by CA XII. The
sequences of CA II and CA XII were aligned (supplementary
Figure S1) and six amino acids (A65S, N67K, I91T, F130A, V134S,
and L203N) in the vicinity of the ligand binding site that differ
between CA II and CA XII were mutated resulting in a chimeric
form of CA II (chCA XII) whose ligand recognition mirrored that
of CA XII.
2.1. Catalytic Properties of chCA XII Closely Mimic CA XII
To ascertain the role of key amino acids in the active site of CA
XII, the thermal stability and catalytic activity of the chCA XII
was measured in a wide pH range and compared to the
properties of CA II and CA XII.[46,47] Six mutations (A65S, N67K,
I91T, F130A, V134S and L203N) in the active site of CA II
resulted in increased thermal stability by 0.5 °C in the pH range
4.5–10.0 (Figure 2A). The CA II and chCA XII were most stable at
pH 6.0–8.0 with melting temperature Tm 55.6�0.1 °C and 56.1�
0.1 °C, respectively. The CA XII had different stability profile with
the maximum Tm=53.6�0.2 °C at pH 6.0. In addition, the chCA
XII had similar maximal catalytic activity as CA II (kcat=
6.0 ×105 s  1), but larger pKa value of His64 by 0.6 units (pKa=
7.9�0.2 for chCA XII and pKa=7.3�0.2 for CA II) as shown in
Figure 2B. The determined maximal catalytic constant of CA XII
was (4.1�0.9) × 105 s  1 with pKa of 7.6�0.2. Interestingly, the
Michaelis-Menten constant of chCA XII (KM=3.6�2.0 mM) was
Figure 1. The general scheme of engineering the chimeric CA XII (chCA XII).
The CA XII-selective inhibitor is shown in gray. The hypothetical inhibitor is
unable to bind to CA II (violet) but is supposed to bind well to chCA XII
(violet-green) and CA XII (green). To obtain chCA XII, six residues in the
active site of CA II were replaced by the ones present in CA XII at the same
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similar to CA XII (KM=3.6�1.5 mM) and differed from CA II
(KM=4.7�1.0 mM) in the pH range 6.8–9.0 (Figure S2). The site-
directed mutagenesis of CA II slightly stabilized the enzyme and
retained the catalytic efficiency (kcat has not changed), but the
pKa of a proton shuttle His64 has increased while the KM value
decreased to approach the CA XII.
Figure 2. Experimental data of stability, catalytic activity and inhibitor binding of CA II (violet squares), CA XII (dark green circles) and chCA XII (light green
squares) by FTSA (panels A, C, E, H), ITC (panels D, F) and SFA (panels G, I) techniques. (A) Thermal stability profiles of CA’s at pH 4.5–10.0. (B) Catalytic
constant of CA dependence on pH in the range 6.0–9.0. (C) Unfolding curves of the proteins at 0, 25 and 200 μM inhibitor 24 concentrations. (D) Raw curves
of CA titrations with inhibitor 13. (E) Thermal shifts of CA melting temperature at increasing inhibitor 24 concentrations up to 200 μM. (F) Integrated titration
curves for inhibitor 13 binding to CA. (G) Acidification curves of spontaneous and catalyzed CO2 hydration reaction by CA at several inhibitor 34
concentrations. (H) Correlations of observed pKd’s between chCA XII and CA XII (R
2=0.90) or CA II (R2=0.24). The theoretically perfect positive correlation is
represented as a black dashed line and linear regression models are shown as green (y=1.03x–0.31) and violet (y=0.52x+3.20) lines. (I) Dose-response
curves of inhibition of CA enzymatic activity by 34. Overall, all shown figures here confirm that the chCA XII protein is recognized by compounds similarly to
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2.2. chCA XII Structure-Affinity Data Recapitulate Wild Type
Interactions
To understand the reasons for affinity and selectivity of
inhibitors targeting CA II and CA XII, we measured interactions
between a series of 63 sulfonamide-based inhibitors and chCA
XII by fluorescent thermal shift assay (FTSA, also called
Thermofluor® or differential scanning fluorimetry) and com-
pared the binding constants to those of CA II and CA XII.[43] We
also used stopped-flow CO2 hydration assay (SFA) to confirm
the inhibitory properties of chemical compounds and isother-
mal titration calorimetry (ITC) to determine the thermodynamic
parameters of binding. As control compounds, we used
commercially available inhibitors - ethoxzolamide (EZA),
acetazolamide (AZM), methazolamide (MZM), naphthalene-2-
sulfonamide (2-NSA) and 1-(4-fluorophenyl)-3-(4-sulfamoyl-
phenyl)urea (U-104/SLC-0111). Figure 2 shows representative
experimental data by FTSA (panels C, E), ITC (panels D, F) and
SFA (panels G, I).
X-ray crystallographic structures of chCA XII were solved in
complex with nine compounds (6, 9, 11, 13, 43, 44, 48, 50, and
52). Electron densities of compounds are shown in Figure S3
and data collection and refinement statistics are presented in
the Table S1. Several compounds bound to CA II and CA XII
have been characterized previously, so we compared the
binding of inhibitors by chCA XII with parental CA II and CA XII
isoforms. Inhibitors used in the study could be arranged to 3
groups according to binding affinities: first that possessed more
than 10-fold selectivity towards CA II over CA XII, second that
possessed more than 10-fold selectivity for CA XII over CA II,
and third that bound CA II and CA XII with similar dissociation
constants. The binding affinities determined by FTSA were in
good agreement with ITC and SFA assays as previously
discussed.[43,46,48] As shown there, we use the Kd values obtained
by FTSA method since this technique provides the most
accurate results.
2.3. CA II-Selective Compounds
The compounds analyzed formed three broad groups. The first
group comprised drug ethoxzolamide (1), non-halogenated,
chlorinated, or fluorinated benzensulfonamides with substitu-
ents at para- (2–16), ortho- (17) or meta- (18–22) positions
(Figure 3, upper part) that bind to CA II more strongly than CA
XII. The binding affinities are provided in Table 1. The majority
of chemical compounds 1–22 (with exception of 2, 4 and 17)
are strong nanomolar inhibitors of CA II (Kd 0.65–67 nM)
possessing up to 200-fold selectivity over CA XII (Kd 37–
1100 nM) and chCA XII (Kd 25–2900 nM). Ureidosulfonamide 2
(U104/SLC-0111) has been previously published as a strong
inhibitor of CA XII with Ki=4.5 nM and a moderate inhibitor of
CA II with Ki=96 nM.
[49] However, we have observed that the
binding affinities of compound 2 were stronger for CA II (Kd
330 nM by FTSA, 150 nM by SFA, 200 nM by ITC) than for CA XII
(Kd 5500 nM by FTSA, 1900 nM by SFA, unobservable Kd by ITC
due to weak binding). According to our results, this compound
inhibits CA II, chCA XII and CA XII weaker than other para-
substituted compounds 3–16.
The observed binding affinities of nonfluorinated com-
pounds 3 and 4 were approximately ten-fold lower than
analogous fluorinated compounds 9 and 10 due higher pKa
value of sulfonamide group of inhibitors 3 and 4.[41] Modifica-
tion of methyl group in 3 and 9 to hydroxy group (compounds
4 and 10) of para-substituent weakened the binding by several
times. The additional morpholine substituent at ortho- position
(compound 17) decreased the binding affinity for CA II by over
1000-fold (Kd 5.9 μM) and chCA XII, CA XII (Kd 100 μM). However,
additional substituents at meta- position (compounds 18–21)
did not have notable change of binding affinity or selectivity.
Dichloro meta-substituted compound 22 also bound CA II 14–
17-fold stronger than chCA XII or CA XII. The binding affinities
of compounds 1–22 representing the first group were similar
for chCA XII and CA XII, thus chCA XII closely mimicked the CA
XII.
Crystal structures of four para-substituted compounds (6, 9,
11, and 13) bound to chCA XII were solved and compared to
the complexes of CA II and CA XII with these inhibitors. The
superimposed binding modes of compounds 6, 9, 11 and 13 in
the active sites of CA II, CA XII and chCA XII are shown in
Figure 4. This group of compounds bound CA II stronger than
CA XII (as well as chCA XII): 6–75-fold (11 vs 830 nM), 9–17-fold
(2.2 vs 37 nM), 11–15-fold (17 vs 250 nM), and 13–29-fold (9.6 vs
280 nM). The fluorinated ring of para-substituted benzenesulfo-
namides (9, 11, 13) could be found in two orientations in the
active site of CA II, chCA XII and CA XII. For example, compound
13 (Figure 4D) had identical orientation of fluorinated ring in
CA II and chCA XII active sites, whereas in CA XII we found two
alternative positions of fluorinated ring. Despite such differ-
ences in the binding mode of compound 13 to CA XII and chCA
XII, the binding affinities were similar. The stronger binding to
CA II could be due to dimethyl pyrimidine interaction with the
phenylalanine side chain Phe131, whereas in chCA XII and CA
XII the position of dimethyl pyrimidine varied. The electron
density of the dimethyl pyrimidine in the crystal structure of
chCA XII was rather weak, suggesting mobility. Compound 11
had two alternative positions of fluorinated ring in active site of
chCA XII, whereas in the crystal structures of CA II and CA XII it
had a single but different position of fluorinated ring (Fig-
ure 4C). In CA II, the side chain of Phe130 reduced the mobility
of the flexible tail. In chCA XII, the electron density of the tail
was also weak. The electron density of 9 bound in chCA XII was
well-defined and compound was modeled in a single orienta-
tion. In the crystal structures of CA II, the position of the ligand
was different. Compound bound in all four subunits of
asymmetric unit of CA XII is found in multiple conformations
with variable positions of the tail (Figure 4B). The position of
the chlorinated benzene ring of compound 6 as in the case of
other chlorosubstituted benzenesulfonamide derivatives was
fixed.[38,50]
There were differences of binding mode in the position of
para-substituent. The positions of the pyrimidine ring in CA XII
differed from that in CA II and chCA XII (Figure 4A). Despite the
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showed the same binding affinities towards chCA XII and CA
XII. Note that the affinities of compound 6 for CA II and CA XII
differed 75-fold. The reason for this was that pyrimidine
substituent of compound 6 in CA II is located in the hydro-
phobic cavity formed by side chains of Phe130, Val134, Leu203
and conservative between CA II and CA XII-Pro201 and Leu197.
The para-substituents of compounds 9 and 13 also had close
interactions with this hydrophobic cavity in active site of CA II.
Active site of CA XII does not contain such hydrophobic cavity
and has alanine instead Phe130 (in CA II), serine instead Val134
and asparagine instead Leu203.
2.4. CA XII-Selective Compounds
The second group of compounds included halogenated
benzensulfonamides 23–34 that possess higher than ten-fold
selectivity for anticancer target CA XII over off-target CA II
(Figure 3 lower part). The chemical compounds are nanomolar
inhibitors of CA XII (as well as chCA XII) as listed in Table 1.
Inhibitors 23–29 have Cl  or Br  atom at the ortho- position,
cyclohexylamino or cyclohexylsulfanyl tail at para- position and
varying tail with amide linkage (except 23) at meta- position.
Compound 23 with methyl substituent at meta- position bound
CAs with Kd 420–5000 nM while compounds 24–29 with amide
linkage at the same position strengthens the binding up to
Figure 3. Chemical structures of compounds 1–34 used in this study arranged according to their selectivity. Benzenesulfonamides 1–22 bound more than 10-
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5000-fold. The strongest binders 24–26 (Kd 0.4–1.9 nM for CA
XII, Kd 0.4-1.6 for chCA XII, and Kd 6.3–31 nM for CA II) bear
phenylsulfanyl or cyclohexylsulfanyl substituent at para posi-
tion. Replacement of cyclohexylsulfanyl to cyclohexylamino tail
decreased the binding affinities approximately ten-fold. In this
study we have synthesized two new inhibitors - 29 (EA12-7)
and 30 (EA11-7) that were analogues to lead compound 26
(EA12-3).[36] We have measured binding affinities towards all 12
catalytically active CAs (Figure 5, Table S2) and showed that
compound 29 (EA12-7) bound all CAs with decreased affinity
compared to 26 (EA12-3), but significantly increased selectivity.
It has 155-fold selectivity towards CA XII (Kd=19 nM) over CA II
(Kd=3000 nM) and bound very weakly or did not bind CAs I, III,
VA, VB, VI, VII and CA XII (Kd�10000–200000 nM). Methylation
of carboxy group at meta-substituent (compound 30) did not
increase affinity or selectivity in comparison to 26 and 29.
In our previous study we showed that fluorinated com-
pounds with bulky substituents on benzensulfonamide ring
have greater affinity for CA XII than CA II.[40] The lead compound
31 (VD11-4-2) of anticancer target CA IX (Kd=50 pM)
[39] bound
CA XII and chCA XII stronger than CA II (Kd=2.9, 6.7 and 56 nM,
respectively). Replacement of cyclooctylamino group to cyclo-
dodecylamino substituent at meta- position and addition of
phenyl ring to para- position (32) decreased the affinity for all
tested CAs. However, the same displacement of hydrophobic
ring and addition of 2-(4-hydroxyphenyl)ethylamino group at
second meta- position with SO2CH2CH2OH tail (33) increased
the size of inhibitor so that it could not fit in the active site of
CA II, but bound to CA XII and chCA XII (Kd 500 and 220 nM).
Another di-meta-substituted benzenesulfonamide bearing
phenyl groups 34 also very weakly bound CA II (Kd 58000 nM)
but stronger to CA XII and chCA XII (Kd=830 and 3300 nM).
Overall, the chCA XII was a suitable model for screening of CA
XII-selective inhibitors. It bound halogenated benzenesulfona-
mides 23–34 with similar affinities as CA XII and accommodated
large compounds with bulky substituents in the active site that
hardly or did not fit in the active site of CA II.
Table 1. The observed dissociation constants (Kd, nM) of CA II-selective compounds 1–22 and CA XII-selective compound 23–34 binding to recombinant
human CA II, chCA XII and CA XII, determined by fluorescent thermal shift assay (pH 7.0, 37 °C) and confirmed by isothermal titration calorimetry (shown in
the parentheses, pH 7.0, 37 °C) and stopped-flow CO2 hydration assay (shown in the parentheses as second value in italic font, pH 7.5, 24 °C).
Compound Carbonic anhydrase Kd [nM]
[a] Kd ratio
No. Lab. name CA II chCA XII CA XII CA XII/CA II
>10-fold selectivity for CA II over CA XII
1 EZA 1.3 25 71 55
2 U-104/ SLC-0111 330 (200, 150) 1800 (780, 300) 5500 (NA, 1900) 17
3 VD12-10 25 330 330 13
4 VD11-31 140 (100) 2200 (330) 2900 (5000) 21
5 E79 4.0 770 910 228
6 E11-8 11 (38) 910 (920) 830 (600) 75
7 E11-18 28 770 330 12
8 E53 67 2860 1100 16
9 VD12-05 2.2 (�12) 86 (44) 37 (47) 17
10 VD10-13 11 310 220 20
11 VD10-35 17 (�12) 250 (180) 250 (140) 15
12 VD10-12 18 670 500 28
13 VD10-50 9.6 (�12) 300 (150) 280 (230) 29
14 VD10-49 0.65 84 120 185
15 VD11-9 1.7 75 76 45
16 VR16-05 2.0 175 83 42
17 VD11-67 5900 100000 100000 17
18 VD11-26 5.9 290 290 49
19 VD11-25 1.7 77 67 39
20 VD11-15 1.2 450 150 125
21 VD12-42 2.9 27 41 14
22 EA4-1 10 140 170 17
>10-fold selectivity for CA XII over CA II CA II/ CA XII
23 E13-4 5000 2000 420 12
24 EA1A-2 31 0.4 1.9 16
25 LJ15-32 6.3 0.77 0.53 12
26 EA12-3 13 1.6 0.4 33
27 EA3-7 420 50 (�12) 24 (�12) 17
28 EA8-7 330 (120) 7.2 (�12) 17 (19) 20
29 EA12-7 3000 (500) 59 (21, <25) 19 (�12, <25) 160
30 EA11-7 530 17 (25) 20 (56) 27
31 VD11-4-2 56 6.7 2.9 19
32 VD12-39 710 25 65 11
33 VD12-65 >200000 220 500 >400
34 VD16-22 58000 (200000) 3330 (910) 830 (500) 70
[a] FTSA data for CA II and CA XII were taken from,[43] except for compounds 23, 25,[36] 34,[52] 2 (U-104/SLC-0111) and 16-determined in this study; NA-not
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2.5. Nonselective Inhibitors
The third group incorporated inhibitors 35–63 that bound to
CA II, chCA XII and CA XII with affinities differing by up to ten-
fold (Figure 6, Table 2). Drugs acetazolamide (35) and methazo-
lamide (36) were nanomolar inhibitors of CA II (Kd 46 and
100 nM) and bound up to 9-fold stronger than chCA XII or CA
XII, while naphthalene-2-sulfonamide (37) similarly bound CA II
stronger than chCA XII and CA XII (Kd for CA II was 770 nM,
while for chCA XII and CA XII - 6700 and 6300 nM, respectively).
The chlorinated benzensulfonamides bearing thiazole (38),
benzimidazole (39) or pyrimidine (40, 41) fragments at para-
position were weaker inhibitors of CA II, chCA XII and CA XII
than acetazolamide (35) and 2,3,5,6-tetrafluoro-4-(phenylthio)
benzensulfonamide (42). The weak binding for CA XII and chCA
XII also shown by ortho-substituted with bulky hydrophobic
groups fluorinated benzenesulfonamides 43 (Kd 10000 and
12500 nM), 44 (Kd 720 and 4000 nM).
Structural arrangement of 43 and 44 in the active site of
chCA XII is compared in Figure 7A. Compounds differed in the
position of the sulfonamide group at Zn(II). Compound 43
contains relatively rigid hydrophobic group in the ortho-
position. Due to its geometry, 43 could not occupy the
canonical position of sulfonamide group in the active site. Only
the positions of the sulfonamide nitrogen atoms of both
compounds coincided. The sulfonamide nitrogen atom of 43
also formed the hydrogen bond with hydroxyl of Thr199 and
the coordination bond with Zn(II). Compound 44 contains in
the ortho-position bulky but flexible hydrophobic cyclooctyla-
mino group. The sulfonamide group of this compound occupies
the canonical position of sulfonamide-based inhibitors in the
active site of human CA isoforms (sulfonamide made two
hydrogen bonds with Thr199 and coordinated Zn(II)).
Fluorinated benzensulfonamides 45–47 with cyclooctylami-
no substituents at ortho- position and varying tails at para-
position also exhibited moderate affinity towards tested CAs (Kd
240–12500 nM). Stronger binders of CA II, chCA XII and CA XII
were meta-, para- di-substituted tri-fluorinated, or chlorinated/
brominated at ortho- position benzensulfonamides 48–63. They
showed similar binding affinities for all three proteins (Kd 3.3–
88 nM for CA II, 0.25–46 nM for chCA XII, and Kd=0.8–330 nM
for CA XII). The crystal structures of compounds 48, 50, 52
bound to chCA XII were determined.
The compound 50 was synthesized by modifying 11: the
hydrophobic substituent was added to the meta- position of
fluorinated ring. Compounds 50 and 11 have similar binding
affinities to CA II (Kd 17 nM) so the impact of additional surface
was not detected. The additional hydrophobic surface at the
meta-position of fluorinated ring has improved the binding
affinity (Kd) of the 50 for CA XII and chCA XII by 20-fold and 30-
Figure 4. X-ray crystallographic structures of CA II-selective compounds
bound to CA II, chCA XII and CA XII. Zn(II) is shown as magenta sphere. Black
line denotes the shape of the active site, whereas blue transparent ellipse
denotes the hydrophilic part of active site which contains water molecules.
Protein side chains and ligands bound to CA II are colored magenta, chCA
XII-light green, CA XII-dark green. (A) Compound 6 bound in the active site
of CA II (PDB: 4KNJ), chCA XII (PDB: 6YH5) and CA XII (PDB: 4KP5). (B)
Compound 9 bound in the active site of CA II (PDB: 4WW6), chCA XII (PDB:
6YHA) and CA XII (PDB: 5MSA). (C) Compound 11 bound in the active site of
CA II (PDB: 4PZH), chCA XII (PDB: 6YH4) and CA XII (PDB: 5MSB). (D)
Compound 13 bound in the active site of CA II (PDB: 4HT0), chCA XII (PDB:
6YHB) and CA XII (PDB: 4HT2).
Figure 5. CA XII-selective inhibitors: 26 (EA12-3), 29 (EA12-7) and 30 (EA11-7) and their affinities for all twelve human CA isoforms determined by fluorescent
thermal shift assay. The white line on the bars represents the limit of affinity determination (Kd 200 μM). Substitution of sulfur atom to nitrogen atom in the
para position decreased the binding affinity for all 12 CAs, but increased inhibitor selectivity for CA XII over CA II from 33-fold to 155-fold and up to 10000-
fold over remaining 10 CA isoforms. However, additional methylation of carboxy group at meta substituent increased the binding affinity for all CAs up to 25-
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fold, respectively. The binding mode of 50 was the same in the
active sites of CA XII and chCA XII, whereas in CA II the position
of the compound was different (Figure 7C). The binding
affinities of 48 and 52 for CA XII were 5–6-fold higher compared
to 11 (10–16-fold for chCA XII). Despite the similar binding
affinities of the compound 52 for CA II, CA XII and chCA XII, the
binding modes also differed as in case of 50. The binding mode
of compound 52 was similar only in the active sites of CA XII
and chCA XII (Figure 7D). The binding mode of 48 was the same
in the active sites of CA II and chCA XII and in one protein chain
out of four in CA XII. In the other three protein chains of CA XII,
the meta-substituent of the compound was located on the
opposite side (Figure 7B). The bulky 48 molecule fully occupied
the middle part of the active site cavity closing the access of
water molecules to the deeper parts of active site. The
consequence of this could be a decreased dissociation rate.[37]
The possible reasons of similar binding affinities of 11 and 50 to
CA II have been analyzed,[37] and the enthalpy-entropy
compensation was observed for this pair of compounds.
Compounds 11 and 50 bound to CA XII differently (compare
Figure 4C and Figure 7C). Compound 50 efficiently filled the
active site of CA XII. Thus, the meta-substituent of 50 was
located in the hydrophobic environment and sterically dis-
placed the remaining part of the compound into the hydro-
philic part of CA XII active site, where the formation of
hydrogen bonds with protein surface is more likely. Such
explanation could be also applicable to the comparison of 11
and 52.
The binding, inhibition and structural studies revealed that
the engineered chCA XII protein mimicked the active site of CA
XII. The experimental dosing/titration curves of chCA XII were
closer to CA XII, but not CA II (Figure 2E, F, I). Figure 2H
summarizes the binding data and shows the correlations
between observed pKd’s of chCA XII and CA II or CA XII. There is
a strong correlation between pKd’s of chCA XII and CA XII with
coefficient of determination R2=0.90, and nearly absent
correlation between binding affinities of chCA XII and CA II with
R2=0.24. The correlations of intrinsic values were also similar to
Figure 6. Chemical structures of compounds 35–63, that bound to CA II and CA XII with similar binding affinities (<10-fold differences). Their binding affinities
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observed ones and were provided in Figure S4. The binding
affinities of several compounds were closer between CA II and
chCA XII, than between chCA XII and CA XII, but all of them
belonged to the group of nonselective inhibitors.
3. Discussion
This study has used a reverse engineering approach to provide
an opportunity to develop selective inhibitors to the difficult
target CA XII. In achieving this it has shed light on outstanding
questions surrounding protein-ligand recognition. Despite dec-
ades of effort on drug development aimed at the carbonic
anhydrases even the apparently most basic questions remain
open. For example, is carbonic anhydrase behaving as rather
rigid protein that does not undergo significant conformational
or other structural changes upon ligand binding, or is the
protein rather flexible where motions of substantial parts are
essential for ligand recognition? Recent studies indicated that
motion is important even for an allegedly “rigid protein”, a
prototypical textbook example such as CA II.[51] In our opinion,
carbonic anhydrase active sites are rather rigid and recognize
ligands primarily via a Lock-and-Key mechanism.[52] However,
the question is largely open and requires further studies to
understand the principles of recognition and enable truly
rational design of high-affinity and high-selectivity compounds.
Several studies[44,45,53] have distinguished the active site
residues that differ between CA II and CA XII and could be
exploited for selective inhibitor design. The first active site
mutants of CA II were generated in the early 1990 s.[54,55] CA II
was used as a model isoform due to simple expression and
purification, ultra-high catalytic activity (kcat=0.6–1.4×10
6 s  1),
moderate thermal stability (Tm 55–59 °C)
[56,57] and off-target
function - it is found in erythrocytes and regulates blood ion
concentrations.[58]
By engineering chCA XII we have shown that six mutations
in the active site of CA II (A65S, N67K, I91T, F130A, V134S, and
L203N) were sufficient to switch its inhibitor recognition profile
to the CA XII. The kinetic studies showed that these mutations
did not affect the catalytic activity (kcat of CA II and chCA XII is
6.0×105 s  1) but increased the pKa value of the proton shuttle
His64 from 7.3 to 7.9. The observed maximal catalytic constant
of CA XII was (4.1�0.9)×105 s  1 and pKa of His64 was 7.6�0.1.
The parameters closely matched the previously published kcat
value of (4.0�1.7)×105 s  1 and pKa of 8.0�0.2 by stopped-flow
spectrophotometry and 7.5�0.1 by 18O-mass spectrometry.[34]
Our previous study showed, that A65T, N67Q, F130Y, V134Q,
and L203T mutations did not affect the pKa value of His64 in CA
II.[59] For this reason, we assumed that I91T mutation increased
the pKa of mutant enzyme and Thr88 (CA XII numbering) was a
key member in catalytic mechanism of CA XII.
Table 2. The observed dissociation constants (Kd, nM) of nonselective compound 35–63 binding to recombinant human CA II, chCA XII and CA XII,
determined by fluorescent thermal shift assay (pH 7.0, 37 °C).
Compound Carbonic anhydrase Kd [nM]
[a] Kd ratio
No. Lab. name CA II chCA XII CA XII CA XII/CA II
Similar binding (<10-fold selectivity)
35 AZM 46 415 130 2.8
36 MZM 100 550 500 5.0
37 2-NSA 770 6700 6300 8.2
38 E11-64 100 625 500 5.0
39 E2 1600 5000 3100 1.9
40 E50 140 2600 1200 8.6
41 E45 120 2900 1100 9.2
42 VD10-18 3.4 50 18 5.3
43 VD12-29-2 2200 12500 10000 4.5
44 VD12-36 230 4000 720 3.1
45 AZ13-2-2 2200 2000 250 0.1
46 VD12-09 1000 500 240 0.2
47 VD12-14 10000 12500 1400 7.0
48 VD12-25-2 64 46 16 0.3
49 VD12-30 42 1.25 5.0 0.1
50 VD12-34 17 12.5 8.3 0.5
51 VD11-28 6.7 33 40 6.0
52 VD10-39b 83 40 25 0.3
53 EA3-3 10 1.7 2.0 0.2
54 EA11-3 10 2.0 1.3 8.0
55 EA4-2 5.0 0.25 0.83 0.2
56 LJ15-22 13 4.0 1.7 7.6
57 LJ14-9 10 0.29 0.8 0.1
58 LJ15-33 5.3 6.7 4.0 0.8
59 EA4-8 20 28 130 6.5
60 EA10-8 40 31 330 8.3
61 LJ15-37 31 26 9.5 0.3
62 EA4-2o 3.3 3.3 3.1 0.9
63 EA12-4 15 10 6.4 0.4
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The chCA XII recognized the substrate with similar KM
constant as CA XII (KM=3.6 mM) as well as observed pKd’s of 63
inhibitors binding to chCA XII were significantly more similar to
CA XII (R2=0.90) than to CA II (R2=0.24). Compounds 9, 11, 13,
48 and 50 occupied similar positions in the active sites of CA XII
and chCA XII, and binding modes differed from CA II. These
crystal structures supported the similar binding by CA XII and
chCA XII, as suggested by binding data. However, several cases
demonstrated different binding modes of the ligand in chCA XII
and CA XII, and the binding modes in chCA XII resembled CA II.
Despite similar position, the key residues interacting with ligand
in CA II and chCA XII differed and contacts between ligand and
protein differed. Detailed interaction analysis of multiple bind-
ing modes as in CA XII could be helpful here.
In this study we have compared inhibitor binding properties
of CA II, chCA XII and CA XII using the observed parameters,
because both isoforms have similar pKa value of zinc-bound
water equal to 7.0–7.1�0.2 at 25 °C.[33,34,60] The binding of
sulfonamide compound to CA occurs only when sulfonamide
group is in the deprotonated form and zinc-bound water in the
active site is protonated.[43,61] For this reason, attention should
be paid to the pKa’s of zinc-bound water molecule and
sulfonamide group of an inhibitor when comparing binding
affinities of several CAs or inhibitors. Structure-affinity correla-
tion analysis should be performed using intrinsic parameters of
binding[41,50,62–66] that are independent on experimental con-
dition (pH, buffer, etc.). Our previous studies with chimeric
carbonic anhydrase VI revealed that intrinsic binding affinities
had a better linear correlation between chCA VI and CA VI than
the observed affinities.[59]
However, in the case of chimeric chCA XII, the pKa of the
Zn(II)-bound water molecule did not differ from CA II or CA XII.
Figure 7. X-ray crystallographic structures of several nonselective compounds bound to CA II, chCA XII and CA XII. Zn(II) is shown as magenta sphere. Black
line denotes the shape of active site, whereas blue transparent area marked the hydrophilic part of active site which contains water molecules. Protein side
chains and ligands bound to CA II are colored magenta, chCA XII-light green, CA XII-dark green. (A) Compounds 43 (PDB: 6YH8) and 44 (magenta, PDB: 6YH6)
bound in chCA XII. (B) Compound 48 bound in CA II (PDB: 4QIY), chCA XII (PDB: 6YH9) and CA XII (PDB: 4QJ0, main orientation (from 4 protein subunits: 3 vs
1)). (C) Compound 50 bound in CA II (PDB: 5DRS), chCA XII (PDB: 6YH7) and CA XII (PDB: 5LLO). (D) Compound 52 bound in CA II (PDB: 5EHE), chCA XII (PDB:
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The pKa values were 6.9 for CA II, 6.9 for chCA XII and 6.8 for CA
XII at 37 °C. Therefore, in the calculation of intrinsic binding
constants, the only reason for the differences from the observed
constants remained the pKa of the compound sulfonamide
amino group. Furthermore, when comparing binding to these
three proteins, the relative ratio of observed or intrinsic values
remained essentially the same and thus Figure 2H compares
the switch of the observed values, while the corresponding
intrinsic constants and their switch is provided in the supple-
mentary materials. The switch was equally well observed in
both approaches.
When studying correlations between compound’s chemical
structure and observed binding affinity for CA II or CA XII, the
studied para-substituted benzenesulfonamides bound to CA II
with more than ten-fold higher affinity than to CA XII. The data
were consistent with other published studies.[42,48,67–69] Despite
the fact that 4-(4-fluorophenylureido)benzenesulfonamide U-
104/SLC-0111[49] (2 in this study) has been tested in patients
with advanced solid tumors and has finished Phase 1 clinical
trial,[70] our study indicates, that as confirmed by three different
assays (FTSA, ITC and SFA), the U-104/SLC-0111 exhibits rather
weak, micromolar, affinity for anticancer target CA XII and binds
it 17-fold weaker than off-target CA II. Recently, Jonsson and
Liljas have expressed doubts about proper experimental data
for promoting the U-104/SLC-0111 compound into preclinical
studies.[71] Our results show that lead compound EA12-3 (26)[36]
is a significantly stronger inhibitor of CA XII (Kd=0.4 nM) and its
newly synthesized analogue EA12-7 (29) possessed significant
selectivity for CA XII. Further studies are needed, by as many
techniques as possible, to confirm the validity of the affinities,
especially because the enzyme inhibition assay is limited by the
concentration of the enzyme and is therefore difficult to apply
it for determination of sub-nanomolar affinities.
4. Conclusions
The detailed thermodynamic and kinetic profiling combined
with X-ray structural studies revealed that CA II-based chimeric
protein chCA XII resembled the active site of CA XII. Amino
acids S67, K69, T88, A129, S133, and N203 were confirmed as
key residues of CA XII for inhibitor recognition, while T88 played
a major role in the catalytic mechanism. A series of 63
sulfonamide compounds bound chCA XII with similar affinities
to CA XII, but not CA II. Structurally, the switch from CA II to CA
XII was very sensitive and therefore both alternative inhibitor
binding positions were observed in the crystal structures of
chCA XII. As a result, chCA XII was shown as a suitable model
for designing CA XII-selective inhibitors, such as compound
EA12-3 and a newly synthesized analogue EA12-7. Our study
provided additional insight to the basis for isoform selectivity of
sulfonamides binding to CA XII, over CA II. The strategy could
potentially be applied to other drug design projects in
medicinal chemistry if the protein was sufficiently rigid.
Experimental Section
Protein Preparation
Carbonic anhydrase protein isoforms I–XIV, including chCA XII were
expressed and purified as described previously.[39] The molecular
weight of enzymes was confirmed by mass-spectrometry, purity
was analyzed by SDS-PAGE and concentrations were determined by
UV-Vis spectrophotometry.
Synthesis of Chemical Compounds
Ethoxzolamide (EZA), acetazolamide (AZM), methazolamide (MZM),
naphthalene-2-sulfonamide (2-NSA), and all starting materials and
reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Compounds 2, 23, 29 and 30 were newly designed and synthesis is
reported in electronic supplementary information. Synthesis of
other chemical compounds was described earlier.[35,36,38–40,42,52,67,72–74]
All compounds were dissolved in dimethyl sulfoxide (DMSO) at 10–
30 mM concentration and diluted in aqueous buffers just prior to
the FTSA, ITC or SFA experiments.
Crystallization
The chCA XII protein was concentrated by ultrafiltration to 28 mg/
mL. Crystallization buffer contained 0.1 M sodium bicine (pH 9.0),
0.2 M ammonium sulfate and 2 M sodium malonate (pH 7.0). The
ligand solutions for crystal soaking were made by mixing of 50 μL
of corresponding reservoir solution and 3 μL of 50 mM ligand
solution (in DMSO).
Data Collection and Structure Determination
All datasets of X-ray diffraction were collected at the EMBL
beamline P13. The datasets were processed by XDS program[75] and
scaled with SCALA.[76] The molecular replacement was made using
MOLREP program.[77] The initial phases were received from PDB
entry 4HT0. The 3D models of compounds were built by AVOGA-
DRO program.[78] The library files with complete chemical and
geometric descriptions of compounds were generated using
LIBCHECK program.[79,80] The models were built using COOT[81] and
refined by REFMAC.[82,83] Coordinates and structure factors have
been deposited to the RCSB Protein Data Bank (PDB). The PDB
access codes, data collection and refinement statistics are listed in
supporting information Table S1.
Fluorescent Thermal Shift Assay
Thermal stability of chCA XII and inhibitor binding affinities were
determined using fluorescent thermal shift assay, also known as
ThermoFluor® or differential scanning fluorimetry (DSF). QIAGEN
Rotor-Gene Q (Corbett Rotor-Gene 6000) cycler with the blue
channel (365�20 nm excitation and 460�15 nm detection) was
used to monitor the fluorescence of 1-anilino-8-naphthalene
sulfonate (ANS) upon carbonic anhydrase unfolding. The temper-
ature of samples was elevated from 25 to 99 °C at a heating rate of
1 °C/min.
Thermal stability experiments at different pH’s (from pH 4.5 to 10.0)
were performed using 10 μM chCA XII in universal buffer (50 mM
sodium acetate, 25 mM sodium borate, 50 mM sodium phosphate
and 50 mM sodium chloride) containing 2% DMSO compound and
50 μM ANS. The melting temperature Tm was determined using a
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Inhibitor binding affinities were determined upon addition of 0–
200 μM (in 2% DMSO) to the 5 μM CA (except 10 μM for CA IV)
solution in 50 mM sodium phosphate, 100 mM sodium chloride
buffer (pH 7.0). The thermal shift data were fitted using a
quantitative model[85,86] yielding the Kd values.
Isothermal Titration Calorimetry
Isothermal titration calorimetry experiments were carried out at
37 °C using VP-ITC and iTC-200 calorimeters. The solution contain-
ing 6–20 μM carbonic anhydrase in the cell was titrated with 60–
200 μM inhibitor solution in the syringe. Experiments were
performed in 50 mM sodium phosphate buffer containing 100 mM
sodium chloride at pH 7.0 with a final DMSO concentration of 2%.
CAs were dialyzed in the reaction buffer before the titrations.
Experimental setup used for VP-ITC instrument: 25 injections of
10 μL every 180 s at reference power of 4 μcal/s and stirring speed
of 260 rpm; iTC200 instrument: 19 injections of 2 μL every 180 s at
reference power of 5 μcal/s and stirring speed of 750 rpm. The
thermodynamic parameters of binding were determined using
NITPIC,[87] SEDPHAT[88] and/or MicroCal Origin software. The first
injection point was deleted in the integrated data and a single
binding model was applied to fit the data.
Stopped-Flow CO2 Hydration Assay
Catalytic properties of chCA XII, CA XII and inhibition constants
were determined using the stopped-flow CO2 hydration assay.
Experiments were performed using Applied Photophysics SX.18
MV-R Stopped-Flow Spectrometer at 24 °C temperature. Saturated
substrate solution was prepared by bubbling CO2 gas into milli-Q
water for 1 hour at room temperature.
The catalytic constant kcat and Michaelis-Menten constant KM of
chCA XII and CA XII in pH range 6.0–9.0 was determined using
25 mM buffer and 30–100 μM indicator pairs with similar pKa values:
Mes and Bromocresol purple (λ 590 nm, pH 6.0–6.4), Mops and
Bromothymol blue (λ 615 nm, pH 6.8–7.1), Hepes and Phenol red (λ
557 nm, pH 7.2–7.8), Tris and m-Cresol purple (λ 575 nm, pH 8.1–
8.4), Ches and Thymol blue (λ 595 nm, pH 8.6–9.0). Solutions also
contained 0.2 M sodium sulfate to maintain ionic strength. Enzyme
concentration was 150–200 nM for chCA XII and 50–150 nM for CA
XII. The saturated substrate solution was diluted with milli-Q water
and final carbon dioxide concentrations were determined according
to Ref.[46] The kinetic parameters were obtained using Lineweaver-
Burk and Michaelis-Menten plots. The pKa values of His64 were




1þ 10pH  pKa (1)
Inhibition of enzymatic activity experiments were performed in
25 mM Hepes buffer, containing 30 μM Phenol red indicator, 0.2 M
sodium sulfate, pH 7.5. The samples consisted of 30–100 nM CA II,
50–200 nM chCA XII, 50–100 nM CA XII and 0–100 μM inhibitor (in
<1% DMSO). The raw curves of time-dependent absorbance
change were fitted using a single exponential model. The rates of
spontaneous CO2 hydration reaction were subtracted from the
observed catalyzed reaction rates. The Kd values were calculated by
fitting dose-response curves to a Morrison equation:[89,90]
CA act: %ð Þ ¼
ð1  
ð½CA� þ ½I� þ Kd  
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi






Synthesis of chemical compounds 2, 23, 29 and 30; sequence
alignment of CA II and CA XII; the dependence of Michelis-
Menten constant on pH; the electron densities of inhibitors
bound to CAs of the crystal structures described in this study;
correlations of intrinsic pKd’s between chCA XII and either CA XII
or CA II; data collection and refinement statistics of chimeric CA
XII complexes with inhibitors 6, 9, 11, 13, 43, 44, 48, 50, and 52;
the observed dissociation constants (Kd, nM) of compounds 26,
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